Skip to main content

Invivyd, Inc.

IVVD
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001832038

In the last 90 days, Invivyd, Inc. insiders filed 0 open-market purchases and 5 sales; 125 institutions reported holding it in 13F filings for Q2 2026, worth $203.5M in total; Maverick Capital is the only superinvestor holding it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Invivyd, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
5 filings
5 insiders, $177.1K in total
Insiders trading
5
Net value
−$177.1K
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Invivyd, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Invivyd, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Sheffield IanDirector–Sep 2, 20261
Elia MarcChief Executive Officer9,248,250IndirectSep 1, 20262
Lee Timothy EdwardChief Commercial Officer178,937Aug 18, 20263
Green JulieChief Human Resources Officer168,937Aug 18, 20263
Duke William E.Chief Financial Officer168,937Aug 18, 20263
Andersen JillChief Legal Officer, Secretary283,774Aug 18, 20263
Allen Robert D. IIIChief Scientific Officer178,765Aug 18, 20263
Mina MichaelCMO and Chief Epidemiologist–Aug 4, 20261
M28 Capital Management LPOther: See Remarks9,248,250IndirectMay 21, 20261
McGuire TerranceDirector3,066,757IndirectMay 21, 20261
McLaughlin Kevin FDirector50,000May 21, 20262
Bolno PaulDirector–May 21, 20261
Royan AjayDirector11,241,580IndirectMay 21, 20261
Berry TamsinDirector–May 21, 20261
Lindenboom ChristineDirector–May 22, 20250
Cotter SaraDirector–May 23, 20240
Gupta SrishtiDirector–May 23, 20240
Adimab, LLC10% Owner21,687,906Jan 22, 20240
Hering DavidChief Executive Officer8,000Dec 20, 20230
Schmidt PeterChief Medical Officer–Dec 20, 20230
Gowler JeremyCOO & CCO–Dec 20, 20230
Price StacyChief Tech. and Manuf. Officer–Dec 20, 20230
Wyzga Michael SDirector–May 25, 20230
Meanwell CliveDirector–May 25, 20230
Heyman Tomas J.Director–May 25, 20230
Dabora RebeccaChief Tech and Manuf Officer–Dec 16, 20220
Mayer HowardDirector–Jun 24, 20220
Miller RedondaDirector–Jun 24, 20220
Thiel Peter10% Owner, Other: See Remarks11,241,580Mar 30, 20220
Mithril II LP10% Owner, Other: See Remarks11,241,580Mar 30, 20220
Mithril II UGP LLC10% Owner, Other: See Remarks11,241,580Mar 30, 20220
Mithril II GP LP10% Owner, Other: See Remarks11,241,580Mar 30, 20220
Henderson JaneChief Financial Officer–Feb 1, 20220
Gerngross Tillman U.Chief Executive Officer27,845,995IndirectFeb 1, 20220
Hershberger ElhamChief Development Officer–Feb 1, 20220
Connolly LynnChief Medical Officer–Feb 1, 20220
Marram Ellen RDirector–Nov 23, 20210
Redmile Group, LLC10% Owner3,390,960IndirectAug 12, 20210
Green Jeremy10% Owner3,390,960IndirectAug 12, 20210
Russo ReneDirector–Aug 9, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Aug 18, 2026 (view filing)8:10 PM ETAug 17-181 dayLee Timothy EdwardChief Commercial OfficerSSale−40.8K$0.7766−$31.7K−18.6%178.9K after2 lots10b5-1
Aug 18, 2026 (view filing)8:10 PM ETAug 17-181 dayGreen JulieChief Human Resources OfficerSSale−40.8K$0.7766−$31.7K−19.4%168.9K after2 lots10b5-1
Aug 18, 2026 (view filing)8:10 PM ETAug 17-181 dayDuke William E.Chief Financial OfficerSSale−40.8K$0.7766−$31.7K−19.4%168.9K after2 lots10b5-1
Aug 18, 2026 (view filing)8:10 PM ETAug 17-181 dayAndersen JillChief Legal Officer, SecretarySSale−68.0K$0.7766−$52.8K−19.3%283.8K after2 lots10b5-1
Aug 18, 2026 (view filing)8:10 PM ETAug 17-181 dayAllen Robert D. IIIChief Scientific OfficerSSale−37.7K$0.7766−$29.3K−17.4%178.8K after2 lots10b5-1
Feb 18, 2026 (view filing)Feb 17-181 dayAllen Robert D. IIIChief Scientific OfficerSSale−37.6K$1.56−$58.7K−24.7%114.5K after2 lots10b5-1
Feb 18, 2026 (view filing)Feb 17-181 dayGreen JulieChief Human Resources OfficerSSale−40.6K$1.56−$63.4K−27.4%107.7K after2 lots10b5-1
Feb 18, 2026 (view filing)Feb 17-181 dayDuke William E.Chief Financial OfficerSSale−40.6K$1.56−$63.4K−27.4%107.7K after2 lots10b5-1
Feb 18, 2026 (view filing)Feb 17-181 dayLee Timothy EdwardChief Commercial OfficerSSale−40.6K$1.56−$63.4K−25.7%117.7K after2 lots10b5-1
Feb 18, 2026 (view filing)Feb 17-181 dayAndersen JillChief Legal Officer, SecretarySSale−67.7K$1.56−$105.7K−27.1%181.7K after2 lots10b5-1
Nov 20, 2025 (view filing)Nov 191 dayMcLaughlin Kevin FDirectorPPurchase+50.0K$2.50+$125.0KNew position50.0K after
Aug 19, 2025 (view filing)Aug 18-191 dayLee Timothy EdwardChief Commercial OfficerSSale−49.7K$0.6022−$29.9K−45.6%59.3K after2 lots10b5-1
Aug 19, 2025 (view filing)Aug 18-191 dayDuke William E.Chief Financial OfficerSSale−49.7K$0.6022−$29.9K−50.2%49.3K after2 lots10b5-1
Aug 19, 2025 (view filing)Aug 18-191 dayGreen JulieChief Human Resources OfficerSSale−49.7K$0.6022−$29.9K−50.2%49.3K after2 lots10b5-1
Aug 19, 2025 (view filing)Aug 18-191 dayAndersen JillChief Legal Officer, SecretarySSale−82.8K$0.6022−$49.8K−49.5%84.4K after2 lots10b5-1
Aug 19, 2025 (view filing)Aug 18-191 dayAllen Robert D. IIIChief Scientific OfficerSSale−45.9K$0.6022−$27.7K−46.4%53.1K after2 lots10b5-1
Dec 31, 2024 (view filing)7:16 PM ETDec 27-314 daysMcGuire TerranceDirectorSSale−273.8K$0.4804−$131.5K−8.2%3.07M after3 lots
Dec 26, 2024 (view filing)7:46 PM ETDec 20-266 daysMcGuire TerranceDirectorSSale−347.6K$0.4744−$164.9K−9.4%3.34M after4 lots
Dec 19, 2024 (view filing)5:54 PM ETDec 17-192 daysMcGuire TerranceDirectorSSale−324.2K$0.4558−$147.8K−8.1%3.69M after3 lots
Dec 16, 2024 (view filing)8:29 PM ETDec 12-164 daysMcGuire TerranceDirectorSSale−190.4K$0.5431−$103.4K−4.5%4.01M after2 lots
Dec 11, 2024 (view filing)Dec 9-112 daysMcGuire TerranceDirectorSSale−485.4K$0.5962−$289.4K−10.4%4.20M after3 lots
May 31, 2024 (view filing)May 292 daysMcGuire TerranceDirectorSSale−112.4K$1.66−$186.6K−2.3%4.69M after
Jan 22, 2024 (view filing)Jan 193 daysAdimab, LLC10% OwnerSSale−5.00M$3.95−$19.8M−18.7%21.7M after
Sep 1, 2022 (view filing)Sep 1Same dayHering DavidChief Executive OfficerPPurchase+8.00K$4.52+$36.2KNew position8.00K after
Aug 19, 2022 (view filing)4:57 PM ETAug 17-192 daysElia Marc and 1 otherDirector, Other: See Footnote 5PPurchase+2.85M$4.28+$12.2M+44.5%9.25M after3 lots
Aug 12, 2021 (view filing)9:25 PM ETAug 102 daysThiel Peter and 3 others10% OwnerPPurchase+2.00M$17.00+$33.9M+21.6%11.2M afterDuplicate filing
Aug 12, 2021 (view filing)9:01 PM ETAug 102 daysRedmile Group, LLC and 1 other10% OwnerPPurchase+1.47M$17.00+$25.0M+76.5%3.39M after
Aug 12, 2021 (view filing)Aug 102 daysRoyan AjayDirector, 10% OwnerPPurchase+2.00M$17.00+$33.9M+21.6%11.2M after
Aug 12, 2021 (view filing)Aug 102 daysMcGuire TerranceDirectorPPurchase+500.0K$17.00+$8.50MNew position497.7K after6 lots